| DC Field | Value | Language |
|---|
| dc.contributor.author | Melnikova, E. V. | - |
| dc.contributor.author | Vodyakova, M. A. | - |
| dc.contributor.author | Pokrovsky, N. S. | - |
| dc.contributor.author | Merkulov, V. A. | - |
| dc.date.accessioned | 2025-11-17T09:41:13Z | - |
| dc.date.available | 2025-11-17T09:41:13Z | - |
| dc.date.issued | 2025 | - |
| dc.identifier.citation | Orthogonal approach and critical quality attributes for gene and cell therapy products / E.V. Melnikova, M.A. Vodyakova, N.S. Pokrovsky, V.A. Merkulov // Research Results in Pharmacology. - 2025. - Vol.11, №3.-P. 87-97. - Doi: 10.18413/rrpharmacology.11.738. - Refer.: p. 94-97. | ru |
| dc.identifier.uri | http://dspace.bsuedu.ru/handle/123456789/65890 | - |
| dc.description.abstract | The paper highlights regulatory recommendations from the FDA, EMA, and WHO, emphasizing the need for validated assays during product release and stability testing | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | orthogonal approach | ru |
| dc.subject | quality attributes | ru |
| dc.subject | quality control | ru |
| dc.subject | cell therapy | ru |
| dc.subject | gene therapy | ru |
| dc.title | Orthogonal approach and critical quality attributes for gene and cell therapy products | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 11, № 3
|
